MEDXF (Medexus Pharmaceuticals) Common Stock: $95.56 Mil (As of Mar. 2026)


MEDXF Medexus Pharmaceuticals Inc MEDXF
58 GF Score
Price $3.51
GF Value $1.32
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals Common Stock?

Medexus Pharmaceuticals MEDXF -1.13% 58 Common Stock is $95.56 Mil as of Mar. 2026. GuruFocus rates MEDXF with a GF Score™ of 58/100 and a GF Value™ of $1.32 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Medexus Pharmaceuticals's quarterly common stock declined from Sep. 2025 ($96.44 Mil) to Dec. 2025 ($96.22 Mil) and declined from Dec. 2025 ($96.22 Mil) to Mar. 2026 ($95.56 Mil).

Medexus Pharmaceuticals's annual common stock increased from Mar. 2024 ($76.39 Mil) to Mar. 2025 ($96.10 Mil) but then declined from Mar. 2025 ($96.10 Mil) to Mar. 2026 ($95.56 Mil).

Medexus Pharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals Common Stock Chart

Medexus Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.69 69.01 76.39 96.10 95.56

Medexus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.10 96.10 96.44 96.22 95.56
MEDXF
58GF Score
Medexus Pharmaceuticals Inc MEDXF
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medexus Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $95.56 Mil mean?
Medexus Pharmaceuticals (MEDXF) has a Common Stock of $95.56 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Medexus Pharmaceuticals and its competitors.
Is Medexus Pharmaceuticals' Common Stock too high?
Medexus Pharmaceuticals' current Common Stock is $95.56 Mil. Overall, Medexus Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Common Stock compare to ZTS and UTHR?
Medexus Pharmaceuticals' Common Stock of $95.56 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Medexus Pharmaceuticals and its competitors. Medexus Pharmaceuticals's current Common Stock is $95.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (MEDXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.32, compared to a current price of $3.51 — trading 165.9% above its estimated fair value. The current Common Stock is $95.56 Mil. Medexus Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Medexus Pharmaceuticals (MEDXF), the current Common Stock is $95.56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of $3.51 is trading 165.9% above its estimated GF Value™ of $1.32. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEDXF:

  • Common Stock: $95.56 Mil
  • GF Value™: $1.32 vs. price of $3.51 (165.9% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medexus Pharmaceuticals Business Description

Other Exchanges P731:GermanyMDP:Canada
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
58GF Score

Get the complete analysis for MEDXF

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.51
Price
$1.32
GF Value